Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
21 results
D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study
D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients
D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab
D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case
D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study
D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey
D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation
D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report
D2.476 - Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months
D1.169 - Monitoring of pulmonary function in pregnant women with severe asthma controlled in a monographic asthma and pregnancy unit
D1.154 - Mepolizumab treatment in a patient with severe eosinophilic granulomatosis with polyangiitis: a case report
D1.155 - Clinical, Functional and Inflammatory Characteristics of Young Adults with Bronchial Asthma Using Conventional Cigarettes, Electronic Nicotine Delivery Systems and Heated Tobacco Products
D1.156 - High relevance of upper airways comorbidities in T2 asthma inflammatory burden
D1.157 - Response to biologic therapy in severe asthma and chronic rhinosinusitis with nasal polyps according to nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity
D1.159 - Comorbidity of Asthma in Chronic Spontaneous Urticaria: Prevalence and Immunological Insights from a Sri Lankan Cohort
D1.160 - Perceptions, Attitudes, and Real-World Use of FENO in Allergy and Asthma Practice: Results of a National Survey from Türkiye
D1.161 - Clinical-epidemiological profile of pediatric difficult-to-control asthma in a tertiary referral center in Brazil
D1.164 - Evaluation of the use of cyclooxygenase-2 inhibitors in patients with AERD
D1.165 - Asthma Predisposition and miRNA Expression in Children with Recurrent Infections
D1.166 - REX-8756 is a First-in-Class Potent and Selective Orthosteric STAT6 Inhibitor That Demonstrates Efficacious Potential and Safety Differentiation in TH2-Mediated Inflammation
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download